File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study

TitleRisk factors associated with adverse drug reactions in hospitalised children: international multicentre study
Authors
KeywordsADRs
Children
Inpatient
Multicentre study
Paediatric
Risk factors
Issue Date2012
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00228/index.htm
Citation
European Journal Of Clinical Pharmacology, 2012, v. 68 n. 5, p. 801-810 How to Cite?
AbstractBackground: Understanding the epidemiology and risk factors of adverse drug reactions (ADRs) is important in order to develop appropriate prevention strategies. This study aimed to identify risk factors associated with ADRs in hospitalised children and recommend strategies to minimise ADRs. Methods: A prospective multicentre cohort study was conducted on paediatric general medical wards in five European and non-European hospitals. ADRs were identified by intensive chart review. Multivariable logistic regression was used to investigate risk factors associated with ADRs. For the risk factor analysis, prescribed drugs were divided into high-risk and low-risk drug groups. Analgesics, anti-epileptics, antibacterials and antimycotics for systemic use, corticosteroids for systemic use and immunosuppressant agents were considered as high-risk groups whereas the remaining drug classes were defined as low-risk drug groups. Results: A total of 1,253 paediatric patients were identified [Australia (n0145), Germany (n0372), Hong Kong (n0 138), Malaysia (n0291), UK (n0307)]. A total of 328 ADRs were observed in 16.7% of patients (186/1,115). Use of five or more low-risk drugs per patient or three or more high-risk drugs was a strong predictor for ADRs (OR 4.7, 95% CI 2.4-9.3; OR 6.5, 95% CI 2.7-16.0 respectively; p<0.001). Older children were more likely to experience ADRs; gender was not significantly associated. Conclusion: To reduce the risk of ADRs in children, clinicians and pharmacists should aim to minimise polypharmacy and be aware of higher ADR risks associated with some drug groups. © Springer-Verlag 2011.
Persistent Identifierhttp://hdl.handle.net/10722/171449
ISSN
2021 Impact Factor: 3.064
2020 SCImago Journal Rankings: 0.845
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorRashed, ANen_US
dc.contributor.authorWong, ICKen_US
dc.contributor.authorCranswick, Nen_US
dc.contributor.authorTomlin, Sen_US
dc.contributor.authorRascher, Wen_US
dc.contributor.authorNeubert, Aen_US
dc.date.accessioned2012-10-30T06:14:19Z-
dc.date.available2012-10-30T06:14:19Z-
dc.date.issued2012en_US
dc.identifier.citationEuropean Journal Of Clinical Pharmacology, 2012, v. 68 n. 5, p. 801-810en_US
dc.identifier.issn0031-6970en_US
dc.identifier.urihttp://hdl.handle.net/10722/171449-
dc.description.abstractBackground: Understanding the epidemiology and risk factors of adverse drug reactions (ADRs) is important in order to develop appropriate prevention strategies. This study aimed to identify risk factors associated with ADRs in hospitalised children and recommend strategies to minimise ADRs. Methods: A prospective multicentre cohort study was conducted on paediatric general medical wards in five European and non-European hospitals. ADRs were identified by intensive chart review. Multivariable logistic regression was used to investigate risk factors associated with ADRs. For the risk factor analysis, prescribed drugs were divided into high-risk and low-risk drug groups. Analgesics, anti-epileptics, antibacterials and antimycotics for systemic use, corticosteroids for systemic use and immunosuppressant agents were considered as high-risk groups whereas the remaining drug classes were defined as low-risk drug groups. Results: A total of 1,253 paediatric patients were identified [Australia (n0145), Germany (n0372), Hong Kong (n0 138), Malaysia (n0291), UK (n0307)]. A total of 328 ADRs were observed in 16.7% of patients (186/1,115). Use of five or more low-risk drugs per patient or three or more high-risk drugs was a strong predictor for ADRs (OR 4.7, 95% CI 2.4-9.3; OR 6.5, 95% CI 2.7-16.0 respectively; p<0.001). Older children were more likely to experience ADRs; gender was not significantly associated. Conclusion: To reduce the risk of ADRs in children, clinicians and pharmacists should aim to minimise polypharmacy and be aware of higher ADR risks associated with some drug groups. © Springer-Verlag 2011.en_US
dc.languageengen_US
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00228/index.htmen_US
dc.relation.ispartofEuropean Journal of Clinical Pharmacologyen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectADRs-
dc.subjectChildren-
dc.subjectInpatient-
dc.subjectMulticentre study-
dc.subjectPaediatric-
dc.subjectRisk factors-
dc.subject.meshAdolescenten_US
dc.subject.meshAdolescent Developmenten_US
dc.subject.meshAsia - Epidemiologyen_US
dc.subject.meshChilden_US
dc.subject.meshChild Developmenten_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshDrug Toxicity - Epidemiology - Physiopathology - Prevention & Controlen_US
dc.subject.meshEurope - Epidemiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHospitals, Generalen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshInfanten_US
dc.subject.meshInfant, Newbornen_US
dc.subject.meshMaleen_US
dc.subject.meshPolypharmacyen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRisk Factorsen_US
dc.titleRisk factors associated with adverse drug reactions in hospitalised children: international multicentre studyen_US
dc.typeArticleen_US
dc.identifier.emailWong, ICK:wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s00228-011-1183-4en_US
dc.identifier.pmid22166934-
dc.identifier.scopuseid_2-s2.0-84864286988en_US
dc.identifier.hkuros207188-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84864286988&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume68en_US
dc.identifier.issue5en_US
dc.identifier.spage801en_US
dc.identifier.epage810en_US
dc.identifier.isiWOS:000303452800037-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridRashed, AN=54584268300en_US
dc.identifier.scopusauthoridWong, ICK=7102513915en_US
dc.identifier.scopusauthoridCranswick, N=6601977827en_US
dc.identifier.scopusauthoridTomlin, S=7003861490en_US
dc.identifier.scopusauthoridRascher, W=7102158639en_US
dc.identifier.scopusauthoridNeubert, A=7003774960en_US
dc.identifier.citeulike10150098-
dc.identifier.issnl0031-6970-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats